Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer
Dr. Cloak is a seasoned executive with over 20 years of commercial leadership experience in the Pharma and Life Science industries. She brings with her a proven track record of driving innovation, operational excellence, sustainable business growth and strategic leadership. Prior to joining Minaris Advanced Therapies, Orla held several leadership positions at Lonza over a 17-year period, most recently serving as Senior Vice President and Head of the Lonza Bioscience business. She holds a Bachelor of Science Degree from University College Dublin and a Doctorate in Microbiology from the University of Ulster.
Iain Baird, Chairman of the Board, Minaris Advanced Therapies commented: "On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies."
Orla Cloak, Chief Executive Officer, Minaris Advanced Therapies commented:"I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to working with the talented team here to build on the company's strong foundations and drive its next phase of growth."
About Minaris Advanced Therapies:
Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing.
Minaris Advanced Therapies is a portfolio company of Altaris.
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com
Media Contact:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
7 hours ago
- Korea Herald
CeraVe Celebrates Two Decades of "Developed with Dermatologists" Skincare: A 20th Birthday Tribute to Skin Barrier Science and Innovations
A Global Celebration Unites Dermatologists, Influencers, and Innovators in New York City to Mark 20 Years of the Iconic Skincare Brand NEW YORK, July 23, 2025 /PRNewswire/ -- It's CeraVe-time to celebrate! CeraVe, the global skincare brand recommended by 80,000 dermatologists worldwide 1, is celebrating a major milestone: 20 years of skin barrier authority, championing barrier health and delivering effective, skin identical ceramide and MVE solutions to provide accessible, therapeutic skincare solutions for everybody everywhere. Over the past two decades, CeraVe has catapulted from a local US derm-backed secret to a global phenomenon, building an inclusive brand that appeals to all genders and generations. What remains unchanged is the brand's foundational insights: that most skin issues are linked to skin barrier disruption, and that skin identical ceramides are key to restoring and maintaining it. That insight began with three core products: Moisturizing Cream, Moisturizing Lotion and Hydrating Cleanser, and today powers a global portfolio of more than 90 barrier-supporting products. This unwavering dedication to its foundational insights, supported by its expertise as a skin barrier authority and its dermatologist-led development, has been the driving force behind CeraVe's remarkable exponential expansion, leading to an impressive 10X growth since its inception, and crossing the $2 billion mark in global sales last year. From the very beginning, CeraVe has revolutionized the skincare landscape as the first brand to be developed with dermatologists - not as a slogan, but as a guiding philosophy and scientific foundation. Every formula, every innovation, every product begins and ends with the expertise of dermatologists, from concept to counter (or store shelf); ensuring clinical efficacy, barrier health and results. "CeraVe's journey began and continues with dermatologists, ensuring superior skin health for all," said Melanie Vidal, Global General Manager, CeraVe. "Through close collaboration, we've transformed their groundbreaking clinical insights into widely accessible, therapeutic solutions that truly enhance lives. As we celebrate two decades of CeraVe and our significant expansion into over 65 countries, we are more dedicated than ever to formulating trusted, barrier-focused products, developed in partnership with dermatologists, for every individual. This momentous occasion not only honors our past achievements but also ignites our drive for another twenty years of pioneering global skin health and advancing the science of the skin barrier." Key to CeraVe's success is the unique formulation that pairs three skin-identical ceramides with trademarked MVE technology – a unique delivery system that releases ingredients gradually, providing hydration that goes 10 layers deep and lasts all day. From the beloved intense hydration of the AM & PM Facial Moisturizing Lotion for dry skin or the barrier-friendly approach of the new Anti-Dandruff Hydrating Shampoo and Conditioner, each product is a direct result of clinical insight and consumer need. This dedication to tailored, dermatologist-developed solutions, consistently infused with ceramides and MVE technology, is why CeraVe has earned such profound trust and widespread recommendations from skin health professionals worldwide. Indeed, in the US and Canada, CeraVe proudly holds the #1 recommended position among key healthcare professionals, including dermatologists, pharmacists, and pediatricians 2, underscoring its broad acceptance and efficacy across various medical specialties. To celebrate this significant accomplishment, CeraVe hosted a global celebration: a birthday bash in New York City that brought together some of the world's most-followed dermatologists, including Dr. Muneeb Shah, Dr. Mamina Turegano, Dr. Evan A. Rieder, Dr. Ted Lain, Professor Michael Cork, Dr. Esther Freedman, Dr. Dustin Portela, Dr. Wallace Nozile, Dr. Zoe Draelos, Dr. Nkem Ugonabo, Dr. Oyetewa Asempa, Dr. Leena Ramani, and Dr. Toral Vaidya, as well as some of TikTok's biggest stars, including Charli D'Amelio (@charlidamelio), and Ari@Home (@ariatinsta). The event was held on World Skin Health Day, allowing CeraVe to further amplify its message of accessible, dermatologist-developed skincare and its dedication to improving skin health worldwide, particularly through its commitment to providing access to dermatological care in under-resourced communities through the brand's Care For All social impact program. As CeraVe looks to the future, the brand remains steadfast in its commitment to dermatologist-developed, science-backed skincare solutions; it continuously pushes the boundaries of innovation. Recent launches highlight groundbreaking new formats within their comprehensive portfolio. For instance, the transformative Blemish Clay-to-Foam Cleanser offers a 3-in-1 solution for blemish-prone skin; it visibly reduces pimples and post-acne marks in just three days. The gentle cleansing Balancing Air Foam Facial Cleanser, designed for combination skin, features Breakthrough Glycolysine™ Technology, providing 8-Hour Oil Control and 24-Hour Hydration. Additionally, CeraVe Blemish Barrier Patches are now available; these leverage advanced hydrocolloid technology with 3 essential ceramides and niacinamide, visibly flattening blemishes in 3 hours, absorbing excess oil, and helping prevent post-acne marks. These innovations collectively underscore CeraVe's dedication to accessible and cutting-edge skincare for all. Beyond skincare, CeraVe marked a significant milestone in the past year by successfully entering the brand new hair care category with its Anti-Dandruff and Gentle Haircare lines. The CeraVe Anti-Dandruff Shampoo and Conditioner when used as a system eliminates up to 100% of visible flakes without disrupting the scalp barrier, while also alleviating symptoms of mild to moderate dandruff and leaving hair healthy and soft. This bold venture has notably been recognized as the most successful hair care launch according to Nielsen data 3. "As one of the first dermatologists involved in the development of CeraVe, I am proud to be part of a brand that has held true to their clinical roots," said Dermatologist Dr. Zoe Draelos. "CeraVe remains committed to involving dermatologists in the development and testing process – that's why it's one of the most effective skincare brands. It will be exciting to see the future brand innovations, as my fellow dermatologists continue to seek out accessible, beneficial skincare products for all." Beyond its scientific rigor, CeraVe has consistently engaged its audience through its signature "medutainment" style – a unique blend of education and entertainment – with a series of noteworthy campaigns over the past two decades. From the iconic Michael CeraVe Super Bowl commercial that playfully embraced the brand's name, to the destigmatizing of dandruff with the "Head of CeraVe" campaign, and most recently, its Sarah V. GOAT mascot, CeraVe has masterfully utilized these platforms to get its core messaging across and re-emphasize its status as a brand developed with dermatologists. 1 Source: Survey conducted among the dermocosmetic market carried out by APLUSA and its other partners between January 2024 and May 2024, involving dermatologists in 29 countries 2 Source: The #1 recommended positions are supported by the following: 3 Source: Nielsen Data About CeraVe: Founded in 2005 and developed with dermatologists, CeraVe is the first and only brand to offer a complete line of products containing essential ceramides and MVE technology to help restore the skin's natural protective barrier. CeraVe has a full line of skincare products to follow the dermatologist-recommended steps of: cleanse, treat, moisturize and protect. The brand's mission is to provide therapeutic skincare for all. For more information, visit the brand on Facebook (@ceraveusa), Instagram (@cerave), TikTok (@cerave), X (@cerave) or at
Korea Herald
7 hours ago
- Korea Herald
Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025
SEOUL, South Korea, July 23, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics, announced today that it will unveil its fully automated PCR testing system, CURECA™, and its data analytics platform, STAgora™, at ADLM 2025 (Association for Diagnostics & Laboratory Medicine), the world's largest diagnostics conference, taking place in Chicago from July 28 to 31. With the introduction of these new technologies, Seegene declares a transformative shift in the global diagnostics paradigm. Automating every step of PCR Testing for enhanced efficiency and accuracy CURECA™ is the world's first system to fully automate the entire PCR testing process – from specimen storage and pre-treatment to nucleic acid extraction, amplification, and result analysis – without any human intervention. Designed for 24/7 continuous operation, the system minimizes human error and dramatically improves the consistency and reliability of the test results. A key breakthrough lies in its fully automated prep module, which addresses one of the most burdensome and error-prone stages in diagnostic workflows. Pre-treatment has traditionally been a major challenge, particularly when dealing with diverse sample types such as urine, blood, sputum, and stool. Lab technicians often carry out repetitive manual tasks over extended hours, and variations in skill level can result in inconsistent outcomes. Stool samples, especially, have posed serious automation barriers due to their viscosity and particulates, requiring heavy manual handling. The prep module of CURECA™ system is the first to fully automate pre-treatment process across all major specimen types – including stool – overcoming longstanding obstacles in laboratory operations. This innovation reduces labor demands, expands sample throughput, and enhances overall operational and cost efficiency. It also shifts the role of laboratory personnel from manual processing to higher-level responsibilities, such as data analysis and clinical interpretation – helping labs better leverage their workforce in high-volume testing environments. In addition, the prep module is applicable beyond PCR diagnostics. It supports pre-treatment for other disciplines, including clinical chemistry and immunoassays, marking a significant step forward in automation across the broader diagnostics market. Its modular architecture allows for flexible configuration and deployment tailored to the size, layout, and needs of each laboratory. STAogra ™ – Real-Time Global Data Integration Empowering Personalized Care Also unveiled at ADLM 2025, STAgora™ is Seegene's statistical platform that collects and analyzes real-time PCR diagnostic data to support clinical decision-making. By aggregating test data uploaded from hospitals around the world, the platform provides integrated insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection. It also offers more than 40 statistical tools tailored for clinical support. With STAgora™, healthcare providers can compare individual patient test results with local and regional epidemiological data, enabling more precise, data-driven treatment strategies. The platform allows clinicians to evaluate infection trends at both patient and community levels, improving the accuracy and speed of diagnosis and care planning. By delivering rapid, reliable insights through this kind of comprehensive analysis, STAgora™ is expected to become an essential analytical tool for clinical decision-making. Expanding Global Collaboration via Technology Sharing and Strategic Partnerships Building on its presence at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ by offering early pilot experiences and establishing new global partnerships. Earlier this year, CURECA™ attracted strong interest at ESCMID Global 2025, one of Europe's leading clinical microbiology and infectious disease congresses. To strengthen its R&D and manufacturing capacity in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA. "CURECA™ and STAgora™ are more than just diagnostics equipment or software—they represent a new global standard that will redefine diagnostics in clinical settings around the world. We will continue to share the many technological assets we've built over the years and based on this foundation, we are committed to driving fundamental innovation across the global diagnostics ecosystem." Said Daniel Shin, Executive Vice President, Chief of Global Sales & Marketing at Seegene. Disclaimer The product is currently in a pre-commercialization phase. The configuration presented at ADLM 2025 is for demonstration purposes only and may differ in functionality, specifications, and components from the final commercial version. This material is intended solely to introduce the technology and does not constitute an advertisement for product sales. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information.
Korea Herald
8 hours ago
- Korea Herald
Global Dental Leaders to Convene in Shanghai for FDI World Dental Congress 2025
SHANGHAI, July 23, 2025 /PRNewswire/ -- The FDI World Dental Congress (WDC), one of the world's premier events for the oral health profession, will take place in Shanghai, China, from September 9–12, 2025, co-hosted by Chinese Stomatological Association and Reed Sinopharm Exhibitions. Organized annually in different countries, the WDC highlights the importance of oral health in securing overall health and well-being and serves as a driving force for international collaboration in dentistry. In recent years, visa-free policies have made China an increasingly popular destination for global travelers. This enhanced accessibility, coupled with Shanghai's global appeal, and FDI's established reputation as the leading global dental event, has already attracted over 10,000 congress delegates for the 2025 edition, with expectations of more than 35,000 professional attendees and visitors from 134 countries and regions. Attendees can look forward to a robust scientific program packed with insights from over 300 world-class speakers and interactive forums on key dental topics. Meanwhile, the FDI WDC 2025 Exhibition is set to be the largest in FDI history, featuring 700 selected exhibitors across 60,000 square meters. Leading global brands such as Haleon, Listerine, LION, and Colgate, along with hundreds of Chinese manufacturers and technology providers, will showcase the most advanced dental equipment and solutions. The exhibition will also spotlight achievements from hospitals and universities, innovations in AI-powered diagnostics, digital dentistry, and 3D printing, providing state-of-the-art solutions to participants. Additionally, the Congress promises exceptional networking opportunities through guided tours designed to connect researchers, clinicians, industry experts, and distributors, fostering partnerships that can advance oral health globally. A Social Program to Remember The social program accompanying WDC25 will provide attendees with a unique cultural experience. Highlights include the Opening Ceremony on September 9, and the Gala Dinner on September 10 invites guests to immerse themselves in Chinese heritage through live performances, regional cuisine, and an evening celebrating cultural elegance. Shanghai Night set for September 11, will be held along the iconic Bund, offering a memorable evening of live music, handcrafted cocktails, and stunning views of Shanghai's dynamic skyline. These events perfectly capture the city's vibrant "East-meets-West" charm and cultural essence. China's Emergence as a Dental Destination While the Congress takes center stage, China's rise as a key market for dentistry cannot be overlooked. Since 2006, China's dental sector has experienced unprecedented growth, outpacing most global markets. The sector's technological transformation has been equally impressive. Chinese dental practices have rapidly adopted cutting-edge solutions including fully digital workflows, fundamentally enhancing treatment accuracy, efficiency, and patient comfort - setting new standards for dental care delivery. Driving Global Oral Health Forward The FDI World Dental Congress continues to set the benchmark for advancing oral health on the global stage. By uniting leaders from across the dental profession, WDC25 will showcase dentistry's most pressing innovations, address key health challenges, and foster greater collaboration to improve oral care around the world.
